Literature DB >> 29023764

Liver diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): A population-based cohort study of 32,839 one-year survivors.

Trine Gade Bonnesen1, Jeanette F Winther2, Klaus K Andersen2, Peter H Asdahl1, Sofie de Fine Licht2, Thorgerdur Gudmundsdottir2, Anna Sällfors Holmqvist3, Laura-Maria Madanat-Harjuoja4,5, Laufey Tryggvadottir6,7, Finn Wesenberg8,9,10, Carsten Heilmann11, Jørgen H Olsen2, Henrik Hasle1.   

Abstract

Information on late onset liver complications after childhood cancer is scarce. To ensure an appropriate follow-up of childhood cancer survivors and reducing late liver complications, the need for comprehensive and accurate information is presented. We evaluate the risk of liver diseases in a large childhood cancer survivor cohort. We included all 1-year survivors of childhood cancer treated in the five Nordic countries. A Cox proportional hazards model was used to estimate hospitalisation rate (hazard) ratios (HRs) for each liver outcome according to type of cancer. We used the risk among survivors of central nervous system tumour as internal reference. With a median follow-up time of 10 years, 659 (2%) survivors had been hospitalised at least once for a liver disease. The risk for hospitalisation for any liver disease was high after hepatic tumour (HR = 6.9) and leukaemia (HR = 1.7). The Danish sub-cohort of leukaemia treated with haematopoietic stem cell transplantation had a substantially higher risk for hospitalisation for all liver diseases combined (HR = 3.8). Viral hepatitis accounted for 286 of 659 hospitalisations corresponding to 43% of all survivors hospitalised for liver disease. The 20-year cumulative risk of viral hepatitis was 1.8% for survivors diagnosed with cancer before 1990 but only 0.3% for those diagnosed after 1990. The risk of liver disease was low but significantly increased among survivors of hepatic tumours and leukaemia. Further studies with focus on the different treatment modalities are needed to further strengthen the prevention of treatment-induced late liver complications.
© 2017 UICC.

Entities:  

Mesh:

Year:  2017        PMID: 29023764     DOI: 10.1002/ijc.31093

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

2.  Hospitalization and mortality outcomes in the first 5 years after a childhood cancer diagnosis: a population-based study.

Authors:  Angela Steineck; Eric J Chow; David R Doody; Beth A Mueller
Journal:  Cancer Causes Control       Date:  2021-04-09       Impact factor: 2.532

3.  The role of liver resection in metastatic nephroblastoma: a systematic review and Meta-regression analysis.

Authors:  Juri Fuchs; Anastasia Murtha-Lemekhova; Markus Kessler; Patrick Günther; Katrin Hoffmann
Journal:  BMC Cancer       Date:  2022-01-18       Impact factor: 4.430

4.  Biliary Rhabdomyosarcoma in Pediatric Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.

Authors:  Juri Fuchs; Anastasia Murtha-Lemekhova; Markus Kessler; Patrick Günther; Alexander Fichtner; Jan Pfeiffenberger; Pascal Probst; Katrin Hoffmann
Journal:  Front Oncol       Date:  2021-09-30       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.